XML 29 R18.htm IDEA: XBRL DOCUMENT
v3.25.3

Sale of Future Royalties | 9 Months Ended
--- | ---
Sep. 30, 2025
Sale of Future Royalties |
Sale of Future Royalties | 11. Sale of Future Royalties ​ In July 2024, the Company entered into a royalty purchase agreement with OMERS. Under the royalty purchase agreement, the Company sold to OMERS a portion of the Company’s future royalty payments and the remaining anniversary payments associated with the Company’s existing license to Lilly relating to OLUMIANT® (baricitinib) for the treatment of alopecia areata. ​ Under the terms of the royalty purchase agreement, the Company received an upfront payment of $26.5 million. In exchange, OMERS acquired a portion of the royalty payable by Lilly to the Company for worldwide net sales of OLUMIANT for the treatment of alopecia areata from April 1, 2024 through the remainder of the royalty term under the Company’s license agreement with Lilly, and 100% of the remaining anniversary milestone payments payable by Lilly to the Company under the license agreement. ​ The Company evaluated the arrangement and concluded that the proceeds from the sale of future royalties should be recorded as deferred income on the condensed consolidated balance sheet, as the criteria for debt classification were not met in accordance with ASC Topic 470. In particular, the Company does not have significant continuing involvement in the generation of the cash flows due to OMERS and there are no guaranteed rates of return to OMERS. The Company recognizes non-cash royalty income under the “units-of-revenue” method in the condensed consolidated statements of operations and comprehensive loss. For the three and nine months ended September 30, 2025, the Company recognized $0.7 million and $2.5 million of non-cash royalty income, respectively. For each of the three and nine months ended September 30, 2024, the Company recognized $0.9 million of non-cash royalty income. As of September 30, 2025, the current and non-current portions of the remaining deferred income recognized under the units-of revenue method were $3.9 million and $17.5 million, respectively. As of December 31, 2024, the current and non-current portions of the remaining deferred income recognized under the units-of revenue method were $3.9 million and $20.0 million, respectively.

X
- References No definition available. + Details
Name: | acrs_RoyaltyPurchaseAgreementDisclosureAbstract
Namespace Prefix: | acrs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of the royalty purchase agreement entered into by the company and the sale of future royalties. + References No definition available. + Details
Name: | acrs_RoyaltyPurchaseAgreementDisclosureTextBlock
Namespace Prefix: | acrs_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration